Vanguard Capital Management’s Perspective Therapeutics CATX Stock Holding History
Bought
Maintained
Sold
Other funds holding CATX
Vanguard Capital Management's CATX Position: Q3 2026 in Review
Vanguard Capital Management reduced its Perspective Therapeutics (CATX) stake by 0.66% in Q3 2026, selling an estimated $88.9K and leaving 4,407,246 shares worth $12.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2648.
Vanguard Capital Management first reported a position in CATX in Q1 2026 and has held it in 3 quarters since. The position peaked at $18.3M in Q1 2026. 120 funds tracked by Wall St. Rank hold CATX as of Q3 2026.
- Vanguard Capital Management held 4,407,246 shares of Perspective Therapeutics worth $12.1M as of Q3 2026.
- Vanguard Capital Management sold 29,326 Perspective Therapeutics shares in Q3 2026, an estimated $88.9K.
- Perspective Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2648 holding.
- Vanguard Capital Management first reported a position in Perspective Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Perspective Therapeutics position peaked at $18.3M in Q1 2026.
- 120 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.